| Bauersachs, Johann |
NCT05697211: ORal IrON Supplementation With Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients With Heart Failure (ORION-HF) |
|
|
| Recruiting | 4 | 50 | Europe | Ferric maltol 30 mg (Feraccru®) | Hannover Medical School, Norgine | Heart Failure, Left-sided, Anemia, Iron Deficiency | 09/24 | 10/24 | | |
HF-REVERT, NCT05350969: Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction |
|
|
| Active, not recruiting | 2 | 294 | Europe, RoW | CDR132L, Placebo to CDR132L | Cardior Pharmaceuticals GmbH | Myocardial Infarction, Acute, Heart Failure, Left Sided | 09/24 | 03/25 | | |
| Vogel, Arndt |
| Active, not recruiting | 3 | 430 | Europe | Ramucirumab, TAS 102 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH | Colorectal Cancer | 12/23 | 06/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Active, not recruiting | 3 | 556 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 09/24 | 10/24 | | |
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) |
|
|
| Recruiting | 3 | 507 | Europe | mFOLFOX6, Leucovorin, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Leucovorin, Oxaliplatin, 5-FU, Irinotecan | Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Colorectal Cancer | 11/27 | 11/30 | | |
| Completed | 2 | 49 | Europe | Nivolumab, TACE | AIO-Studien-gGmbH, Bristol-Myers Squibb | Carcinoma, Hepatocellular, Hepatic Carcinoma, Hepatocellular Cancer | 10/21 | 12/21 | | |
| Completed | 2 | 128 | Europe | Durvalumab, Gemcitabine, Cisplatin, Tremelimumab | AIO-Studien-gGmbH, AstraZeneca | Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable, Gallbladder Carcinoma Non-Resectable | 03/22 | 03/22 | | |
|
NCT05101629: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy |
|
|
| Active, not recruiting | 2 | 32 | Europe | Pembrolizumab, Keytruda, Lenvatinib Capsules, Lenvima | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel, Merck Sharp & Dohme LLC | Hepatocellular Carcinoma | 10/24 | 12/24 | | |
IMMUWIN, NCT04522544: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC |
|
|
| Recruiting | 2 | 55 | Europe | Tremelimumab, Durvalumab, Y-90 SIRT, DEB-TACE | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca, Hannover Medical School | Hepatocellular Carcinoma Non-resectable, HCC | 03/25 | 09/25 | | |
NCT04511455: Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Recruiting | 2 | 45 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 06/25 | 12/25 | | |
NCT04238637: Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) |
|
|
| Recruiting | 2 | 50 | Europe | Durvalumab, Other Name: MEDI4736, Tremelimumab, Study treatment | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca | Intrahepatic Cholangiocarcinoma | 12/25 | 12/25 | | |
NCT05174650: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements |
|
|
| Recruiting | 2 | 37 | Europe | Atezolizumab, Tecentriq, Derazantinib, ARQ 087 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Intrahepatic Cholangiocarcinoma | 12/25 | 08/26 | | |
| Recruiting | 1/2 | 70 | Europe | DKN-01 300 mg, DKN-01 600 mg, Sorafenib | Johannes Gutenberg University Mainz, Leap Therapeutics, Inc. | Hepatocellular Carcinoma | 08/21 | 08/22 | | |
| Recruiting | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 06/24 | 07/24 | | |
| Recruiting | N/A | 1000 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 05/32 | 05/32 | | |
| Könecke, Christian |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 03/24 | 03/24 | | |
| Hendrik, Eggers |
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients |
|
|
| Recruiting | 3 | 250 | Europe | Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel | Jena University Hospital, Bayer | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 02/25 | 08/26 | | |
